Capecitabine in the management of colorectal cancer

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 79-89

  Hirsch, Bradford R ^a   Yousuf Zafar, S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Capecitabine; Colon cancer; Colorectal cancer; Rectal cancer; Xeloda

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; THYMIDINE PHOSPHORYLASE;

ABDOMINAL PAIN; ADD ON THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DEHYDRATION; DERMATITIS; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TRANSFORMATION; DRUG TUMOR LEVEL; FATIGUE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HAND FOOT SYNDROME; HEALTH CARE COST; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; ILEUS; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RECOMMENDED DRUG DOSE; RECTUM SURGERY; REIMBURSEMENT; REVIEW; RNA SYNTHESIS; STOMATITIS; THROMBOCYTOPENIA; UPREGULATION;

EID: 79957819449     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMR.S11250     Document Type: Review

References (64)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA CancerJ Clin. 2010;60(5):277-300.
2. Johnston PG, Kaye S. Capecitabine: a novel agent for the treatment ofsolid tumors. Anticancer Drugs. 2001;12(8):639-646.
3. National Comprehensive Cancer Network. The NCCN Clinical PracticeGuidelines in Oncology: Colon Cancer (Version 2.2011). Available from:http://www.nccn.org/professionals/physician_gls/recently_updated.asp.Accessed November 29, 2010
4. National Comprehensive Cancer Network. The NCCN Clinical PracticeGuidelines in Oncology: Rectal Cancer (Version 2.2011). Available from:http://www.nccn.org/professionals/physician_gls/recently_updated.asp.Accessed November 29, 2010.
5. Tanaka M, Yoshida S, Saneyoshi M, Yamaguchi T. Utilization of 5-fluoro-2'-deoxyuridine triphosphate and 5-fluoro-2'-deoxycytidinetriphosphate in DNA synthesis by DNA polymerases alpha and betafrom calf thymus. Cancer Res. 1981;41(10):4132-4135.
6. Matsuoka H, Ueo H, Sugimachi K, Akiyoshi T. Preliminary evidencethat incorporation of 5'-fluorouracil into RNA correlates with antitumorresponse. Cancer Invest. 1992;10(4):265-269.
7. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidinecarbamate, capecitabine, which generates 5-fluorouracil selectively intumours by enzymes concentrated in human liver and cancer tissue. EurJ Cancer. 1998;34(8):1274-1281.
8. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabinein tumor following oral administration to colorectal cancer patients.Cancer Chemother Pharmacol. 2000;45(4):291-297.
9. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H.Induction of thymidine phosphorylase activity and enhancement ofcapecitabine efficacy by taxol/taxotere in human cancer xenografts. ClinCancer Res. 1998;4(4):1013-1019.
10. Endo M, Shinbori N, Fukase Y, et al. Induction of thymidine phosphorylaseexpression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int JCancer. 1999;83(1):127-134.
11. Morita T, Tokue A. Biomodulation of 5-fluorouracil by interferonalphain human renal carcinoma cells: relationship to the expression ofthymidine phosphorylase. Cancer Chemother Pharmacol. 1999;44(2):91-96.
12. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-rayirradiation induces thymidine phosphorylase and enhances the efficacyof capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res.1999;5(10):2948-2953.
13. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics ofcapecitabine. Clin Pharmacokinet. 2001;40(2):85-104.
14. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologicstudy of intermittent twice-daily oral therapy with capecitabinein patients with advanced and/or metastatic cancer. J Clin Oncol.1998;16(9):2977-2985.
15. Reigner B, Watanabe T, Schüller J,et al. Pharmacokinetics of capecitabine(Xeloda) in Japanese and Caucasian patients with breast cancer.Cancer Chemother Pharmacol. 2003;52(3):193-201.
16. Judson IR, Beale PJ, Trigo JM, et al. A human capecitabine excretionbalance and pharmacokinetic study after administration of a single oraldose of 14C-labelled drug. Invest New Drugs. 1999;17(1):49-56.
17. Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokineticsof capecitabine and its metabolites following oral administrationin cancer patients. Clin Cancer Res. 1998;4(4):941-948.
18. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differencesforthe tolerability profiles of fluoropyrimidines. J Clin Oncol. 2008;26(13):2118-2123.
19. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy ofoxaliplatin and fluoropyrimidine regimens with or without bevacizumabas first-line treatment of metastatic colorectal cancer: results of theTREE Study. J Clin Oncol. 2008;26(21):3523-3529.
20. Midgley R, Kerr DJ. Capecitabine: have we got the dose right? Nat ClinPract Oncol. 2009;6(1):17-24.
21. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvanttreatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696-2704.
22. Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from arandomized phase III trial of capecitabine plus oxaliplatin versus bolus5-FU/LV for stage III colon cancer (NO16968): no impact of age ondisease-free survival (DFS) [abstract 284]. Proceedings of the Gastrointestinal Cancers Symposium; 2010 Oct 1-3; Washington, DC, USA.
23. Roche Investor Update 2010. Roche provides results on Avastin inadjuvant colon cancer. Available from: http://www.roche.com/investors/ir_update/inv-update-2010-09-18b.htm. Accessed November 29, 2010.
24. Glynne-Jones R, Dunst J, Sebag-Montefiore D. The integration oforal capecitabine into chemoradiation regimens for locally advancedrectal cancer: how successful have we been? Ann Oncol. 2006;17(3):361-371.
25. National Cancer Institute. Clinical Trials. Phase III randomized studyof adjuvant chemotherapy comprising capecitabine and oxaliplatinversus standard follow-up care in patients with clear margins aftercomplete resection of locally advanced rectal cancer. Available from:http://www.cancer.gov/clinicaltrials/CRUK-CHRONICLE. AccessedNovember 29, 2010.
26. Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer StudyGroup. Preoperative versus postoperative chemoradiotherapy for rectalcancer. N Engl J Med. 2004;351(17):1731-1740.
27. De Paoli A, Chiara S, Luppi G, et al. Capecitabine in combination withpreoperative radiation therapy in locally advanced, resectable, rectalcancer:a multicentric phase II study. Ann Oncol. 2006;17(2):246-251.
28. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine(Xeloda) and concomitant boost radiotherapy in patients with locallyadvanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66(3):762-771.
29. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperativechemoradiation using oral capecitabine in locally advanced rectalcancer. Int J Radiat Oncol Biol Phys. 2002;54(2):403-408.
30. Kim JC, Kim TW, Kim JH, et al. Preoperative concurrent radiotherapywith capecitabine before total mesorectal excision in locallyadvanced rectal cancer. Int J Radiat Oncol Biol Phys. 2005;63(2):346-353.
31. Hofheinz R, Wenz F, Post S, et al. Capecitabine (Cape) versus5-fluorouracil (5-FU)-based (neo-)adjuvant chemoradiotherapy (CRT)for locally advanced rectal cancer (LARC): safety results of a randomized,phase III trial [abstract 4014]. J Clin Oncol. 2009;27(15S):4014.
32. Rödel C, Liersch T, Hermann RM, et al. Multicenter phase II trialof chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol.2007;25(1):110-117.
33. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabineand oxaliplatin before chemoradiotherapy and total mesorectalexcision in MRI-defined poor-risk rectal cancer: a phase 2 trial. LancetOncol. 2010;11(3):241-248.
34. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of twoneoadjuvant chemoradiotherapy regimens for locally advanced rectalcancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J ClinOncol. 2010;28(10):1638-1644.
35. Machiels JP, Duck L, Honhon B, et al. Phase II study of preoperativeoxaliplatin, capecitabine and external beam radiotherapy in patientswith rectal cancer: the RadiOxCape study. Ann Oncol. 2005;16(12):1898-1905.
36. Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W,Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, andradiation for rectal cancer. J Clin Oncol. 2003;21(16):3098-3104.
37. Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al. A phase II studyof capecitabine and irinotecan in combination with concurrent pelvicradiotherapy (CapIri-RT) as neoadjuvant treatment of locally advancedrectal cancer. Br J Cancer. 2007;96(6):912-917.
38. Klautke G, Küchenmeister U, Foitzik T, et al. Concurrent chemoradiationwith capecitabine and weekly irinotecan as preoperative treatmentfor rectal cancer: results from a phase I/II study. Br J Cancer. 2006;94(7):976-981.
39. Machiels JP, Sempoux C, Scalliet P, et al. Phase I/II study of preoperativecetuximab, capecitabine, and external beam radiotherapy in patientswith rectal cancer. Ann Oncol. 2007;18(4):738-744.
40. Rödel C, Arnold D, Hipp M, et al. Phase I-II trial of cetuximab, capecitabine,oxaliplatin, and radiotherapy as preoperative treatment in rectalcancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1081-1086.
41. Twelves C, Gollins S, Grieve R, Samuel L. A randomised crossovertrial comparing patient preference for oral capecitabine and5-fluorouracil/leucovorin regimens in patients with advanced colorectalcancer. Ann Oncol. 2006;17(2):239-245.
42. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oralversus intravenous palliative chemotherapy. J Clin Oncol. 1997;15(1):110-115.
43. Ling W, Fan J, Ma Y, Ma Y, Wang H. Capecitabine-based chemotherapyfor metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010. DOI:10.1007/s00432-010-0954-0.
44. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabineversus intravenous fluorouracil plus leucovorin as first-line treatment in605 patients with metastatic colorectal cancer: results of a randomizedphase III study. J Clin Oncol. 2001;19(8):2282-2292.
45. Van Cutsem E, Twelves C, Cassidy J, et al. Xeloda ColorectalCancer Study Group. Oral capecitabine compared with intravenousfluorouracil plus leucovorin in patients with metastatic colorectalcancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097-4106.
46. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III studyof capecitabine plus oxaliplatin compared with fluorouracil/folinic acidplus oxaliplatin as first-line therapy for metastatic colorectal cancer.J Clin Oncol. 2008;26(12):2006-2012.
47. Porschen R, Arkenau HT, Kubicka S, et al; AIO Colorectal StudyGroup. Phase III study of capecitabine plus oxaliplatin compared withfluorouracil and leucovorin plus oxaliplatin in metastatic colorectalcancer: a final report of the AIO Colorectal Study Group. J Clin Oncol.2007;25(27):4217-4223.
48. Díaz-Rubio E, Tabernero J, Gómez-España A, et al; Spanish CooperativeGroup for the Treatment of Digestive Tumors Trial. Phase III studyof capecitabine plus oxaliplatin compared with continuous-infusionfluorouracil plus oxaliplatin as first-line therapy in metastatic colorectalcancer: final report of the Spanish Cooperative Group for the Treatmentof Digestive Tumors Trial. J Clin Oncol. 2007;25(27):4224-4230.
49. Ducreux M, Bennouna J, Hebbar M, et al. Eff icacy and safetyfindingsfrom a randomized phase III study of capecitabine (X) +oxaliplatin(O) (XELOX) vs infusional 5-FU/LV + O (FOLFOX-6)for metastatic colorectal cancer (MCRC) [abstract 4029]. J Clin Oncol.2007;25(18S):4029.
50. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin(XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin(FOLFOX-4) as second-line therapy in metastatic colorectal cancer:a randomized phase III noninferiority study. Ann Oncol. 2008;19(10):1720-1726.
51. Koopman M, Antonini NF, Douma J, et al. Sequential versus combinationchemotherapy with capecitabine, irinotecan, and oxaliplatin inadvanced colorectal cancer (CAIRO): a phase III randomised controlledtrial. Lancet. 2007;370(9582):135-142.
52. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trialof irinotecan plus infusional, bolus, or oral fluoropyrimidines in firstlinetreatment of metastatic colorectal cancer: results from the BICC-Cstudy. J Clin Oncol. 2007;25(30):4779-4786.
53. Köhne CH, De Greve J, Hartmann JT, et al. Irinotecan combined withinfusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib orplacebo in the first-line treatment of patients with metastatic colorectalcancer. EORTC study 40015. Ann Oncol. 2008;19(5):920-926.
54. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23-44.
55. Díaz-Rubio E, Burris H, Douillard JY, et al; The X-Act Study Group.Safety of capecitabine (X) compared to fluorouracil/leucovorin(5-FU/LV) for the adjuvant treatment of elderly colon cancer patients(pts) [abstract 3737]. J Clin Oncol. 2004;22(14S):3737.
56. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment forpatients older than 70 years with metastatic colorectal cancer: an oncopazcooperative group study. J Clin Oncol. 2005;23(13):3104-3111.
57. Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab asfirst-line treatment in elderly patients with metastatic colorectal cancer.Br J Cancer. 2010;102(10):1468-1473.
58. Rosati G, Cordio S, Bordonaro R, et al. Capecitabine in combinationwith oxaliplatin or irinotecan in elderly patients with advancedcolorectal cancer: results of a randomized phase II study. Ann Oncol.2010;21(4):781-786.
59. Hennig IM, Naik JD, Brown S, et al. Severe sequence-specific toxicitywhen capecitabine is given after fluorouracil and leucovorin.J Clin Oncol. 2008;26(20):3411-3417.
60. Chu E, Schulman KL, Zelt S, Song X. Costs associated with complicationsare lower with capecitabine than with 5-fluorouracil in patientswith colorectal cancer. Cancer. 2009;115(7):1412-1423.
61. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysisof adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C coloncancer: the X-ACT trial. Br J Cancer. 2006;94(8):1122-1129.
62. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis ofXELOX for metastatic colorectal cancer based on the NO16966 andNO16967 trials. Br J Cancer. 2009;101(1):12-18.
63. Chu E, Schulman KL, McKenna EF Jr, Cartwright T. Patients withlocally advanced and metastatic colorectal cancer treated with capecitabineversus 5-fluorouracil as monotherapy or combination therapywith oxaliplatin: a cost comparison. Clin Colorectal Cancer. 2010;9(4):229-237.
64. Velenik V, Ocvirk J, Omejc M, et al. Neoadjuvant bevacizumab, capecitabine,and radiotherapy in locally advanced rectal cancer: interim resultsof a phase II CRAB trial [abstract e14006]. J Clin Oncol. 2010;28(15):e14006.